Blood Res.  2017 Jun;52(2):145-148. 10.5045/br.2017.52.2.145.

The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea

Affiliations
  • 1Department of Laboratory Medicine, Pusan National University School of Medicine and Biomedical Research Institute Research Institute, Pusan National University Hospital, Busan, Korea.
  • 2Department of Laboratory Medicine, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Yangsan, Korea. iskim0710@gmail.com
  • 3Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
  • 4Division of Gastroenterology and Hepatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.

Abstract

No abstract available.


MeSH Terms

Budd-Chiari Syndrome*
Complement System Proteins*
Hemoglobinuria, Paroxysmal*
Korea*
Complement System Proteins

Figure

  • Fig. 1 Abdominal computed tomography evidence of Budd-Chiari Syndrome. (A) The liver shows heterogeneous enhancement and multiple ill-defined hypodense lesions with venous congestion. (B) Non-obstructive thrombus in inferior vena cava stent and multiple enhancing nodules at the liver are seen.

  • Fig. 2 Flow cytometric analysis of granulocytes using FLAER. (A) As a control setting, there was no evidence of decreased (type II PNH cells) or absent (type III PNH cells) expression of FLAER. (B) In this patient, decreased (42.4%) and absent (57.0%) FLAER fractions were detected, suggesting that 99.4% of PNH granulocyte clones had a FLAER deficiency, which is consistent with classic PNH. Abbreviations: FITC, fluorescein isothiocyanate; FLAER, fluoresceinlabeled proaerolysin; PNH, paroxysmal nocturnal hemoglobinuria.


Reference

1. Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003; 38:364–371.
Article
2. Smalberg JH, Darwish Murad S, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica. 2006; 91:1712–1713.
Article
3. Valla D, Dhumeaux D, Babany G, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology. 1987; 93:569–575.
Article
4. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995; 333:1253–1258.
Article
5. Hoekstra J, Leebeek FW, Plessier A, et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol. 2009; 51:696–706.
Article
6. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 110:4123–4128.
Article
7. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004; 350:552–559.
Article
8. Singer AL, Locke JE, Stewart ZA, et al. Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transpl. 2009; 15:540–543.
Article
9. Brodsky A, Mazzocchi O, Sánchez F, Khursigara G, Malhotra S, Volpacchio M. Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation. Exp Hematol Oncol. 2012; 1:26.
Article
10. Mandala E, Lafaras C, Goulis I, Tsioni K, Georgopoulou V, Ilonidis G. Treatment of a patient with classical paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome, with complement inhibitor eculizumab: Case Report. Hippokratia. 2013; 17:81–84.
11. Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010; 78:211–230.
Article
12. Lee JW, Jang JH, Kim JS, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013; 97:749–757.
Article
13. Ki M, Choi HY, Kim KA, Kim BH, Jang ES, Jeong SH. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int. 2016; 36:1067–1073.
Article
14. Navenot JM, Muller JY, Blanchard D. Investigation of the survival of paroxysmal nocturnal hemoglobinuria red cells through the immunophenotyping of reticulocytes. Transfusion. 1998; 38:337–342.
Article
15. Richards SJ, Hill A, Hillmen P. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom. 2007; 72:291–298.
Article
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr